Search Resources (English): Adverse drug effect

Results 1 - 10 of 21

Results

Canada's adverse drug reaction database

Provides a searchable database that holds information from all adverse drug reaction (ADR) reports currently held in Health Canada's CADRIS (Canadian Adverse Drug Reaction Information System) database, which monitors adverse drug reactions in drugs approved for the Canadian market.

Published: 1965-2004
Canadian adverse reaction newsletter

Provides a newsletter that contains adverse reaction information and is published quarterly, in January, April, July and October of each year. Alerts health professionals to potential signals detected through the review of case reports submitted to Health Canada, and also disseminates information on suspected adverse reactions to health products occurring in humans before comprehensive risk-benefit evaluations and regulatory decisions are undertaken.

Important safety concerns on the use of Diane-35  
http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/diane-35_hpc-cps-eng.pdf

Discusses an article regarding important safety concerns on the use of cyproterone acetate (marketed as Diane-35 in Canada, and as Dianette in the United Kingdom).

 (See Details)
Published: 2002
Post-market surveillance of therapeutic drugs in Canada  
http://www.whp-apsf.ca/en/documents/adrBackground.html
Discusses the importance of an effective post-market surveillance system of therapeutic drugs. Lists problems with the current system, and argues that improvements will only occur when there is greater consumer involvement. (See Details)
Published: 2005
The Evra (ethinyl estradiol/norelgestromin) contraceptive patch: estrogen exposure concerns  
http://www.cmaj.ca/cgi/content/full/174/2/164
Reviews the Evra patch and the potential for excess estrogen exposure raises concerns about the risks of adverse effects, which include nausea, breast tenderness and venous thromboembolism. (See Details)
Published: 2006
Diane-35 (cyproterone acetate): safety concerns  
http://www.cmaj.ca/cgi/content/full/168/4/455
Discusses warnings regarding the drug, Diane-35, and the drug's risk of venous thromboembolism. States that Diane-35 should be reserved for temporary use in women with serious acne and should not be used solely as an oral contraceptive. (See Details)
Published: 2003
Newly developed drugs pose more dangers for patients  
http://www.cwhn.ca/resources/afi/drugs.html
Explains that unexpected serious reactions often turn up after a drug appears on the market and that it can take years of use before doctors discover serious drug toxicity. (See Details)
Published: 2003
Keeping tabs on drug reactions  
http://www.cwhn.ca/resources/drugs/reactions.html
Explains why PharmaWatch and Women and Health Protection are calling on Health Canada to establish a more effective system for reporting and monitoring adverse drug reactions. (See Details)
Published: 2004
Synthesising licensing data to assess drug safety  
http://bmj.bmjjournals.com/cgi/content/full/328/7438/518
Argues that if trials done by pharmaceutical companies for licensing purposes had to include adequate data on harms and ineffectiveness the medical community could learn much more quickly what they need to know about new drugs. Contends that the risks of hormone replacement therapy would have been revealed much earlier if better use had been made of existing evidence, and as such, women have been needlessly exposed to an increased risk of heart disease. (See Details)
Published: 2004
Estrogen and breast cancer: a warning to women
Chronicles the sixty-year attempt to "cure" menopause with female hormones and the forty-year history of chemical contraception. Details the list of medical and epidemiological studies that show estrogen to be a potential carcinogen.
Published: 1993